Halozyme Therapeutics Inc (NASDAQ:HALO)
| 45.51 BATS BZX Real-Time Price As of 3:15pm ET |  -0.90 / -1.94%Today’s Change | 12.71 Today|||52-Week Range 56.40 | +6.56% Year-to-Date |
Latest HALO News | Press Releases
| Why Halozyme Therapeutics Is Trading 14% Higher Today Feb 24 / MotleyFool.com - Paid Partner Content | Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript Feb 23 / MotleyFool.com - Paid Partner Content |
| Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls Feb 24 / Zacks.com - Paid Partner Content | Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More Feb 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 46.41 |
| Today’s open | 46.24 |
| Day’s range | 44.67 - 46.72 |
| Volume | 48,161 |
| Average volume (3 months) | 1,868,950 |
| Market cap | $6.1B |
Data as of 3:15pm ET, 03/02/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +73.32% |
| Earnings growth (next 5 years) | +59.50% |
| Revenue growth (last year) | +36.53% |
| P/E ratio | 50.0 |
| Price/Sales | 22.58 |
| Price/Book | 40.55 |
Competitors
| ---- | ||
| KODKodiak Sciences Inc | -9.02 | -6.68% |
| BPMCBlueprint Medicines ... | -0.29 | -0.29% |
| IOVAIovance Biotherapeut... | -1.96 | -4.97% |
Data as of 3:15pm ET, 03/02/2021
Financials
| Next reporting date | May 11, 2021 |
| EPS forecast (this quarter) | $0.32 |
| Annual revenue (last year) | $267.6M |
| Annual profit (last year) | $129.1M |
| Net profit margin | 48.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
